Debbane Raymond's Form 4 filing
Crescent Biopharma, Inc. (CBIO) · filed Jul 30, 2024
- Accession no.
- 0000950170-24-088020
- Filed
- Jul 30, 2024, 5:16 PM ET
- Trade date
- Jul 26-30, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $315.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Debbane RaymondCIK 0001053890 | 10% Owner |
| Invus Public Equities Advisors, LLCCIK 0001340096 | 10% Owner |
| Invus Public Equities, L.P.CIK 0001340097 | 10% Owner |
| Siren, L.L.C.CIK 0002005245 | 10% Owner |
| Invus Global Management, LLCCIK 0002005369 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 26, 2024 | Common Stock | SSaleDisposed | −258,335 | $0.2417 | −$62,439.57 | 8,330,729 | Direct | |
| Jul 29, 2024 | Common Stock | SSaleDisposed | −363,949 | $0.2353 | −$85,637.2 | 7,966,780 | Direct | |
| Jul 30, 2024 | Common Stock | SSaleDisposed | −756,835 | $0.2209 | −$167,184.85 | 7,209,945 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.